BRAF, a member of a serine/threonine kinase protein family, serves as an immediate downstream effector of RAS in the MAPK signaling cascade, a signal transduction pathway that transmits mitogenic ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

Black Diamond Therapeutics has found a partner for its deprioritized solid tumor candidate. Five months after cutting support ...

BRAF gene fusions are much more common than BRAF ... it has two other assets in early development that target the BRAF-MAPK signalling pathway, including IPN01194 that started phase 1 earlier ...

One of the standard treatment options for melanoma over the last ten years has been to simultaneously target both BRAF mutations and MEK. These two genes are part of the MAPK signalling pathway ...

The trial, targeting advanced cancers with MAPK pathway mutations ... or in those who have not responded to BRAF/MEK inhibition. Pasithea plans to present updated PK and PD data during the ...

[email protected] Cytological fine-needle aspiration diagnosis of thyroid nodules can be improved by testing for BRAF, RET/PTC and other mutations. BRAF is a reliable diagnostic marker for ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...